Resolvins fall into several sub-classes based on the straight chain PUFA from which they are formed and/or a unique aspect of their structure. The Resolvin Ds are metabolites of the 22-carbon PUFA, DHA ; the resolvin Es are metabolites of the 20-carbon PUFA, EPA ; the resolvin Dn-6DPA are metabolites of the DPA isomer, osbond acid ; the resolvin Dn-3DPA are metabolites of the DPA isomer, clupanodonic acid ; and the resolvin Ts are metabolites of clupanodonic acid that, in contrast to, possess a 17R-hydroxyl residue. Certain isomers of RvDs are termed aspirin-triggered resolvin Ds because their synthesis is initiated by a drug-modified COX2 enzyme to form 17-hydroxyl rather than 17-hydroxyl residue of the ReVEs; however, an as yet unidentified cytochrome P450 enzyme may also forms this 17-hydroxy intermediate and thereby contribute to the production of AT-RvEs. All of the cited resolvins except the RvDsn-6DPAs are metabolites of omega-3 fatty acids. The following oxygenase enzymes may be responsible for metabolizing PUFA to resolvins: 15-lipoxygenase-1, possibly 15-lipoxygenase-2, 5-lipoxygenase, cyclooxygenase-2, and certain Cytochrome P450 monooxygenases.
Resolvin Ds
RvDs are poly-hydroxyl metabolites of DHA. To date, six RvDs, which vary in the number, position, and chirality of their hydroxyl residues as well as the position and cis-trans isomerism of their 6 double bonds, have been described. These are: RvD1, RvD2, RvD3, RvD4, RvD5, and RvD6.. These metabolites are formed by a wide range of cells and tissues by the initial metabolism of DHA to 7S-hydroperoxy-DHA and 4S-hydroperoxy-DHA by a 15-lipoxygenase followed by the further metabolism of the two intermediates by ALOX5 to their 17-hydroperoxy derivatives; these di-hydroperoxy products are further altered to the cited RvDs by these oxygenases or by non-enzymatic reactions and the conversion of their peroxy residues ubiquitous cellular peroxidases.
Resolvin Es
RvEs are di- or tri-hydroxyl metabolites of EPA. To date, four RvEs have been described: RvE1, 18S-Rv1, RvE2, and RvE3. Resolvin Es are formed in manner similar to AT resolving Ts. COX-2 modified in activity by aspirin or atorvastatin or, alternatively, a microbial or possibly mammalian cytochrome P450 monoxygenase metabolizes EPA to its 18R-hydroperoxy derivative; this intermediate is then further metabolized by ALOX5 to a 5,6 epoxide which is hydrolyzed enzymatically or non-enzymatically to RvE1 and 18S-RvE1 or reduced to RvE2; alternatively the 18R-hydroperoxide is converted to the 17R,18Svicinaldiol product, RvE3.
Human platelets pretreated with aspirin or atorvastatin metabolize the omega-3 DPA, clupanodonic acid by aspirin-treated or atorvastatin-treated COX2 to a 13S-hydroperoxy intermediate ; RvT2 ; RvT3 and RvT4. Subsequent studies found that these four RvTs are also formed by mixtures of human neutrophils and vascular endothelium cells and, additionally, are detected in the infected tissues of rodents and humans.
Putative mechanisms
Following tissue injury, the inflammatory response is a protective process to promote restoration of the tissue to homeostasis. Resolution of inflammation involves various specialized lipid mediators, including resolvins. Resolvins are under laboratory research for their potential to act through G protein-coupled receptors RvD1 and AT-RvD1 act through the Formyl peptide receptor 2, which is also activated by certain lipoxins and is therefore often termed the ALX/FPR2 receptor; 2) RvD1, AT-RVD1, RvD3, AT-RvD3, and RvD5 act through the GPR32 receptor which is now also termed the RVD1 receptor; 3) RvD2 acts through the GPR18 receptor also now termed the RvD2 receptor; and 4) RvE1 and the 18 analog of RvE1 are full activators while RvE2 is a partial activator of the CMKLR1 receptor. All of these receptors activate their parent cells through standard GPR-mobilized pathways. RvE1, 18-RvE1, and RvE2 inhibit the Leukotriene B4 receptor 1 which is the receptor for inflammation-promoting PUFA metabolites such as LTB4 and the R stereoisomer of 12-HETE; by inhibiting the action of these pro-inflammatory mediators.
Preliminary research
Resolvin metabolites of EPA, DHA, and DPA and the maresin and protectin D1 metabolites of DHA are under basic research for their potential influences on inflammation. One human study reported no increase in urine or plasma resolvin content after consumption of fish oil compared to a non-omega-3 oil, either before or after challenge with bacteriallipopolysaccharide known to induce an inflammatory reaction. Preliminary studies in people with cancer, kidney disease or cystic fibrosis while receiving dietary PUFA or fish oil supplements indicated improvement of inflammation biomarkers, possibly resulting from resolvins.
